The health consequences of hepatitis G virus (HGV) infection in humans remain to be determined. Inconsistent results of HGV and the risk of hepatocellular carcinoma (HCC) have been found in retrospective case-control studies. No prospective studies have addressed this issue. A prospective study including 18,244 men in Shanghai, China, was conducted to assess the role of HGV infection in HCC development. Serum HGV RNA and hepatitis B surface antigen (HBsAg) were assessed in 127 HCC case patients and 660 matched control subjects drawn from the cohort. Four patients with HCC (3.1%) and 21 control subjects (3.2%) were positive for serum HGV RNA. The presence of HGV RNA in prediagnostic serum was not associated with the risk of HCC (odds ratio, 1.0; 95% confidence interval, 0.3-2.9). No association between HGV RNA positivity and HCC risk was observed in either HBsAgpositive carriers or noncarriers. It is concluded that HGV infection plays no role in HCC development in this high-risk population.
such as Japan, Italy, and Spain, HCV infection is a more important risk determinant [3] .
The recently discovered hepatitis G virus (HGV) is an RNA virus belonging to the Flaviviridae family [7, 8] . Chronic viremia may develop after infection. Exposure to blood products is a recognized route of transmission in humans [8] [9] [10] . The reported prevalence rates of chronic HGV infection range from 1% to 3% in most populations [11] . Epidemiologic data have indicated that patients with HGV seropositivity were also likely to be coinfected with HBV or HCV or both [10, 12] .
Although clinical studies have failed to implicate HGV as an oncogenic virus [12, 13] , epidemiologic studies of HGV infection and HCC risk have reported mixed results. Recently, among nonAsians of Los Angeles County, California, we noted a statistically significant association between chronic HGV infection and the risk of HCC [11] . These case-control findings are comparable with results of a case-control study in northern Italy [14] but are in disagreement with the null findings from another case-control study among black South Africans [15] .
To assess the etiologic role of HGV in HCC development, we conducted a prospective cohort study involving 18,244 middleaged and older men in Shanghai, a high-risk population with age-standardized incidence rates of HCC in men and in women of 28 and 10 per 100,000 person-years, respectively [1] . The uniqueness of the present study includes the following: (1) prediagnostic serum samples collected р10 years before the diagnosis of HCC; (2) population-based study design; (3) large sample size, with р10 years of follow-up; and (4) negligible rate of HCV infection among HCC case patients, thus avoiding the possible confounding effect of HCV on HGV-HCC association. 
Material and Methods
Case patients and control subjects. The design of the cohort study has been described elsewhere [16] . In brief, all men 45-64 years old residing in 4 geographically defined small areas of Shanghai were invited to participate in a prospective study of diet and cancer. A total of 18,244 men (∼80% of eligible subjects) were recruited from January 1986 through September 1989. A 10-mL blood sample and 1 void urine sample were collected at recruitment after an extensive in-person interview that emphasized dietary exposures. Follow-up of this cohort has been accomplished through routine review of the population-based Shanghai Cancer Registry records, routine review of death certificates, and annual recontact of all surviving cohort members.
By 1 September 1996, the study had accumulated 179,467 personyears of observation. One hundred and twenty-eight incident cases of HCC had been identified, which were diagnosed on the basis of histopathologic confirmation ( ), elevated serum a-fetoprotein n p 17 with consistent clinical and radiologic history ( ), positive comn p 22 puterized axial tomography scan or ultrasonography or both with consistent clinical history ( ), or by death certificate only n p 86 ( ) . n p 3
For each of the cases, multiple cancer-free control subjects, who were matched to the index cases by date of birth (within 2 years), time of blood sample collection (within 1 month), and neighborhood of residency at recruitment, were randomly selected from the cohort. Ten control subjects were matched to each of the first 6 identified cases of HCC, whereas 5 control subjects were matched to each of the remaining 122 cases.
Laboratory tests. All serum samples were tested blindly, identified only by codes, without regard to case or control status. We tested all study samples for the presence of hepatitis B surface antigen (HBsAg), using a standard radioimmunoassay (AUSRIA; Abbott Laboratories, Abbott Park, IL).
Serum samples were tested for the presence of HGV RNA by the nested reverse transcriptase-polymerase chain reaction (RT-PCR) method [17] . Viral RNA was extracted (RNA-NOW-LM; Biogentex, Seabrook, TX) from 100 mL of serum, precipitated with isopropyl alcohol, washed once with 75% ethanol, and resuspended in 50 mL of diethyl pyrocarbonate-treated water. Ten microliters of the dissolved RNA were used for a single-tube RT-PCR, using external primers sense 5 -AAGGTGGTGGATGGGTGATGACA G-3 and antisense 5 -AGAGAGACATTGAAGGGCGACGTG-3 at 42ЊC for 45 min, followed by 35 cycles of 1 min at 95ЊC, 1 min at 55ЊC, and 1 min at 72ЊC. Each 100-mL RT-PCR reaction mixture contained 10 mM Tris buffer (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 mM each dNTP, 0.01% (wt/vol) gelatin, 1 mM each primer, 16 U of RNasin (Promega, Madison, WI), 2 U of avian myeloblastosis virus RT (Promega), and 2 U of AmpliTaq DNA polymerase (Perkin-Elmer Cetus, Branchurg, NJ).
Ten microliters of the first-round PCR product were used for the second round, using internal primers sense 5 -ACAGGGTTGGTA-GGTCGTAAATCC-3 and antisense 5 -TGGACCGTACGTGG-GCGTCGTTTG-3 . Each 100 mL of the second-round PCR reaction mixture contained 10 mM Tris buffer (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 200 mM each dNTP, 0.01% (wt/vol) gelatin, 1 mM each primer, and 2 U of AmpliTaq DNA polymerase. After 35 cycles of 1 min at 95ЊC, 1 min at 55ЊC, and 1 min at 72ЊC, 25 mL of the second-round PCR product were analyzed for 208-bp DNA by electrophoresis. The sequence of the PCR product has been confirmed [18] .
Because of the inadequate quantities of serum, the serologic status for HGV RNA or HBsAg (or both) was missing for 1 case patient and 5 control subjects who were not matched to that specific case. Therefore, 127 case patients and 660 matched control subjects were included in the present study.
Statistical analysis. Data were analyzed by conditional logistic regression methods [19] . The association of infection to HCC was measured by odds ratio (OR) with 95% confidence intervals. An HGV-infected individual was defined as one exhibiting the presence of HGV RNA in serum. To assess the interaction effect between HGV and HBV infections on the risk of HCC, an HGV-HBV product term was included in the multivariate logistic regression model. We also examined the associations of infection to HCC stratified by the time interval between blood sample collection and cancer diagnosis. Similarly, an HGV-time product term was included in the logistic model to assess the possible differential effect of HGV on risk of HCC diagnosed within 5 years of versus у5 years after enrollment. All P values are 2-sided.
Results
The mean age (‫ע‬SD) of patients with HCC at the time of diagnosis was 62.2 ‫)7.4ע(‬ years, whereas the corresponding age of control subjects was 62.1 ‫)7.4ע(‬ years. The average time interval between blood sample collection and the diagnosis of HCC was 4.5 years (range, 0.1-10.2 years). Table 1 presents the associations between the presence of HGV RNA or HBsAg in prediagnostic serum and the risk of HCC. Four (3.1%) of 127 patients with HCC exhibited HGV RNA in serum, compared with 21 (3.2%) of 660 control subjects. The presence of HGV RNA in prediagnostic serum was not associated with the risk of HCC (OR, 1.0;
). Sev-P p .96 enty-seven (61%) of 127 patients with HCC and 63 (10%) of 660 control subjects tested positive for serum HBsAg. The presence of HBsAg in serum was associated with a 16-fold increase for the risk of HCC, compared with those who were negative for HBsAg ( ). P ! .0001 We examined the association between HGV infection and HCC risk by HBsAg status. Of HBsAg-negative subjects, 2 (4.0%) of 50 patients with HCC and 17 (2.8%) of 597 control Table 3 presents the association of HGV and HBV infections and the risk of HCC stratified by time interval between collection of blood sample and diagnosis of cancer (i.e., duration of follow-up). Irrespective of duration of follow-up, the presence of HGV RNA in serum was not associated with the risk of HCC ( , for difference in the risk of HCC diagnosed P p .49 within 5 years of vs. у5 years after enrollment). On the other hand, the magnitude of the elevated OR for HCC associated with HBsAg positivity increased in cases diagnosed у5 years after enrollment, compared with those with !5 years of followup (table 3) , but the difference in the risk of HCC was not statistically significant ( ). P p .36
Discussion
To our knowledge, this is the first prospective cohort study that has examined the relationship between HGV infection and subsequent risk of HCC. We observed a prevalence rate of 3% for serum HGV RNA in patients with HCC and a comparable prevalence rate in the general population. We conclude that there is no relationship between the presence of HGV RNA in prediagnostic serum and the risk of HCC in middle-aged and older men in Shanghai.
The present study had several strengths. First, prediagnostic serum samples that were collected a maximum of 10 years before cancer diagnosis minimized the possible effect of heightened susceptibility to HGV infection in the immunocompromised liver of patients with subclinical or clinical HCC. Second, the population-based design minimized selection bias. Third, there were a sufficient number of cases to prospectively assess the role of HGV infection in HCC development with relatively high statistical power. Fourth, the negligible role of HCV in HCC development in this study population enabled us to address HGV in relation to HCC, without possible confounding by HCV coinfection.
A number of studies in diverse populations have examined the prevalence of HGV RNA in serum among volunteer blood donors or healthy adults. In most populations (East Asia, Australia, Western Europe, and North America), the reported prevalence rate of chronic HGV infection is relatively low, ranging from 1% to 3% [8, [20] [21] [22] . However, higher rates have been observed among blood donors in São Paulo, Brazil (9%) [23] and among blacks in Johannesburg, South Africa (12%) [15] . We observed a prevalence rate of 3% among control subjects in the current study, which is comparable with the rates in blood donors in Taiwan and mainland China (2%-5%) [24] [25] [26] .
To our knowledge, only 3 case-control studies and no previous prospective studies have examined the relationship between chronic HGV infection and the risk of HCC. Lightfoot et al. [15] did not observe any increase in HCC risk among HGV RNA-positive versus -negative black South African subjects. These findings are in contradiction to results from a study in Northern Italy [14] and another study conducted by our group among non-Asians in Los Angeles [11] . The latter studies noted a 4-5-fold increased risk of HCC with HGV RNA positivity that was unexplained by HBV or HCV infections [11, 14] .
In this prospective study in a high-risk population for HCC, we found no association among HGV infection and the risk of HCC. The apparently inconsistent findings between studies could be attributed to one or a combination of reasons. First, the observed association between HGV and HCC risk in retrospective case-control studies is the result of heightened susceptibility to HGV infection in the immunocompromised livers of patients with HCC. Indeed, in the present study, the prevalence of HGV RNA in patients with HCC with !5 years of follow-up (3 [4.2%] of 72) seems to be higher than that in patients with a longer follow-up period (1 [1.8%] of 55), although the difference between the 2 was not statistically significant (
). In addition, HGV has no etiologic role in P p .42 HCC development. For example, the statistical associations between HGV infection and HCC risk in US blacks and whites [11] and northern Italians [14] could be reflections of a positive correlation between infection with HGV and an as-yet-unidentified oncogenic hepatitis virus(es) in the 2 populations.
Clinical studies have shown that after up to 9 years of followup, individuals who were infected with HGV alone did not exhibit elevated serum alanine aminotransferase levels [9, 10] . Furthermore, multiple studies have shown that chronic hepatitis B or C patients who were positive for serum HGV RNA experienced a clinical course and biochemical characteristics of hepatitis similar to those who were not coinfected with HGV [9, 10, 13] . Thus, evidence from clinical studies and the present prospective epidemiologic investigation strongly suggest that HGV is not oncogenic.
The present study confirms previous observations that chronic HBV infection is a causal factor of HCC in Chinese populations [2, 3] . The presence of serum HBsAg (a marker of chronic HBV infection) was associated with a 16-fold increase in the risk of HCC in this high-risk population.
In summary, the present study demonstrated that HGV RNA positivity in prediagnostic serum was not associated with subsequent risk of HCC development in adult Chinese men in Shanghai. This study adds to the increasing body of evidence that HGV is not hepatocarcinogenic.
